Kevin Vincent Grimes, MD
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Grimes’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G51537 · Current
Licensed to practise in California · since 1983 · expires 2027-10-31 · Brown University Program in Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$3,003
Medicare paid this office $3,003 for 41 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 32 | $2,139 | $53 |
Who their Medicare patients are
41 Original Medicare patients in 2024. Average age 73 · Women 49% · Also on Medicaid 42% · Health risk score 1.22. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 66% · Diabetes 41%.
The office billed $6,533, Medicare allowed $4,090 and paid $3,003; for 53 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 41 | 53 | 73 | 1.22 | $6,533 | $3,003 |
| 2023 | 66 | 91 | 75 | 1.60 | $13,454 | $5,867 |
| 2022 | 54 | 59 | 71 | 1.55 | $19,950 | $4,791 |
| 2021 | 49 | 58 | 70 | 1.53 | $19,288 | $4,463 |
| 2020 | 56 | 60 | 67 | 1.63 | $16,076 | $2,855 |
| 2019 | 65 | 83 | 71 | 1.65 | $5,145 | $3,243 |
| 2018 | 60 | 67 | 72 | 1.69 | $4,180 | $2,600 |
| 2017 | 64 | 81 | 67 | 2.44 | $7,009 | $3,315 |
| 2016 | 57 | 67 | 73 | 1.61 | $6,365 | $2,781 |
| 2015 | 73 | 84 | 70 | 1.46 | $9,711 | $3,169 |
| 2014 | 82 | 109 | 70 | 1.53 | $13,304 | $4,327 |
| 2013 | 110 | 137 | 68 | 1.74 | $16,962 | $5,170 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Short return visit (20+ min) | 57 | $4,757 | $59 |
2022: 1 service
| Short return visit (20+ min) | 34 | $2,078 | $58 |
2021: 1 service
| Short return visit (20+ min) | 33 | $2,192 | $55 |
2020: 1 service
| Short return visit (20+ min) | 36 | $1,691 | $43 |
2019: 1 service
| Short return visit (20+ min) | 60 | $2,681 | $39 |
2018: 2 services
| Short return visit (20+ min) | 40 | $1,567 | $35 |
| Short return visit (20+ min) | 19 | $829 | $44 |
2017: 1 service
| Short return visit (20+ min) | 61 | $3,134 | $40 |
2016: 1 service
| Short return visit (20+ min) | 52 | $2,552 | $42 |
2015: 1 service
| Short return visit (20+ min) | 63 | $2,858 | $39 |
2014: 1 service
| Short return visit (20+ min) | 80 | $4,282 | $40 |
2013: 1 service
| Short return visit (20+ min) | 105 | $4,844 | $37 |
Medicaid work
$342 in 2023
Medicaid paid $342 for 42 billed services this clinician did in 2023, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 42 | $342 |
| 2023 | 42 | 1 | 15 | $342 |
| 2022 | 12 | 1 | 12 | $167 |
| 2021 | 14 | 1 | 13 | $211 |
| 2019 | 28 | 1 | 16 | $520 |
| 2018 | 13 | 1 | 12 | $196 |
See the largest Medicaid services in earlier years
2022
| Short return visit (20+ min) | 12 | $167 |
2021
| Short return visit (20+ min) | 14 | $211 |
2019
| Short return visit (20+ min) | 28 | $520 |
2018
| Short return visit (20+ min) | 13 | $196 |
Drugs they prescribed that Part D paid
$1,062
Pharmacies billed $1,062 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
45 generic and fewer than 11 brand-name prescriptions · $1,062 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Simvastatin | 13 | $185 | $14 |
Year by year
| 2024 | 53 | 15 | None | None | $1,062 |
| 2023 | 53 | 19 | None | None | $1,594 |
| 2022 | 54 | 14 | None | None | $4,073 |
| 2021 | 38 | 13 | 0% (0) | None | $4,313 |
| 2020 | 139 | 33 | None | 9% | $7,547 |
| 2019 | 348 | 71 | None | 13% | $27,840 |
| 2018 | 328 | 68 | 4% (12) | 16% | $27,692 |
| 2017 | 309 | 69 | 6% (18) | 13% | $17,800 |
| 2016 | 579 | 81 | 5% (26) | 11% | $26,266 |
| 2015 | 694 | 115 | 4% (26) | None | $49,636 |
| 2014 | 757 | 121 | 2% (13) | None | $62,314 |
| 2013 | 973 | 136 | 3% (26) | None | $65,030 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2020: 3 drugs
| Levothyroxine | 11 | $345 | $31 |
| Metformin | 11 | $139 | $13 |
| Atorvastatin | 11 | $132 | $12 |
2019: 9 drugs
| Labetalol | 14 | $711 | $51 |
| Atorvastatin | 30 | $455 | $15 |
| Amlodipine Besylate | 21 | $404 | $19 |
| Levothyroxine | 12 | $315 | $26 |
| Metformin | 20 | $269 | $13 |
| Lisinopril | 26 | $190 | $7 |
| Pantoprazole | 11 | $173 | $16 |
| Tamsulosin | 12 | $166 | $14 |
| Losartan | 12 | $130 | $11 |
2018: 6 drugs
| Atorvastatin | 35 | $512 | $15 |
| Amlodipine Besylate | 19 | $168 | $9 |
| Labetalol | 11 | $141 | $13 |
| Lisinopril | 18 | $130 | $7 |
| Losartan | 15 | $109 | $7 |
| Omeprazole | 12 | $107 | $9 |
2017: 6 drugs
| Januvia | 12 | $4,671 | $389 |
| Omeprazole | 15 | $390 | $26 |
| Atorvastatin | 21 | $350 | $17 |
| Levothyroxine | 11 | $258 | $23 |
| Venlafaxine Hcl Er | 15 | $131 | $9 |
| Lisinopril | 14 | $82 | $6 |
2016: 16 drugs
| Atorvastatin | 50 | $920 | $18 |
| Desmopressin Acetate | 13 | $569 | $44 |
| Levothyroxine | 25 | $464 | $19 |
| Valsartan | 15 | $416 | $28 |
| Baclofen | 14 | $318 | $23 |
| Omeprazole | 27 | $306 | $11 |
| Metoprolol | 22 | $301 | $14 |
| Unifine Pentips | 12 | $215 | $18 |
| Hydrochlorothiazide | 20 | $175 | $9 |
| Finasteride | 17 | $159 | $9 |
| Lisinopril | 19 | $94 | $5 |
| Fluticasone Propionate | 12 | $80 | $7 |
| Furosemide | 13 | $78 | $6 |
| Simvastatin | 16 | $61 | $4 |
| Fenofibrate | 12 | $52 | $4 |
| Amlodipine Besylate | 15 | $38 | $3 |
2015: 15 drugs
| Nexium | 12 | $10,724 | $894 |
| Duloxetine | 12 | $4,265 | $355 |
| Atorvastatin | 53 | $905 | $17 |
| Gabapentin | 20 | $471 | $24 |
| Levothyroxine | 16 | $467 | $29 |
| Omeprazole | 36 | $346 | $10 |
| Quinapril | 12 | $314 | $26 |
| Fluticasone Propionate | 21 | $256 | $12 |
| Losartan | 26 | $214 | $8 |
| Amlodipine Besylate | 26 | $200 | $8 |
| Lisinopril | 30 | $197 | $7 |
| Pantoprazole | 11 | $190 | $17 |
| Carvedilol | 26 | $175 | $7 |
| Metformin | 16 | $158 | $10 |
| Simvastatin | 23 | $133 | $6 |
2014: 16 drugs
| Gabapentin | 34 | $1,620 | $48 |
| Omeprazole | 64 | $1,308 | $20 |
| Atorvastatin | 39 | $907 | $23 |
| Levothyroxine | 17 | $476 | $28 |
| Fluticasone Propionate | 19 | $375 | $20 |
| Losartan | 25 | $363 | $15 |
| Simvastatin | 23 | $345 | $15 |
| Quinapril | 12 | $338 | $28 |
| Ipratropium | 12 | $289 | $24 |
| Metformin | 14 | $251 | $18 |
| Carvedilol | 22 | $232 | $11 |
| Pantoprazole | 13 | $134 | $10 |
| Metoprolol | 14 | $130 | $9 |
| Amlodipine Besylate | 23 | $102 | $4 |
| Lisinopril | 14 | $101 | $7 |
| Citalopram Hbr | 13 | $91 | $7 |
2013: 28 drugs
| Nexium | 16 | $8,623 | $539 |
| Spiriva | 18 | $5,086 | $283 |
| Lantus Solostar | 11 | $2,949 | $268 |
| Lovaza | 16 | $2,499 | $156 |
| Gabapentin | 33 | $1,304 | $40 |
| Losartan | 26 | $1,146 | $44 |
| Omeprazole | 48 | $959 | $20 |
| Atorvastatin | 28 | $947 | $34 |
| Clopidogrel | 19 | $760 | $40 |
| Fluticasone Propionate | 28 | $713 | $25 |
| Metformin | 23 | $543 | $24 |
| Metoprolol | 14 | $487 | $35 |
| Lisinopril | 57 | $485 | $9 |
| Finasteride | 17 | $371 | $22 |
| Simvastatin | 31 | $355 | $11 |
| Paroxetine | 11 | $328 | $30 |
| Amlodipine Besylate | 42 | $326 | $8 |
| Levothyroxine | 15 | $251 | $17 |
| Metoprolol | 21 | $222 | $11 |
| Hydrocodone-Acetaminophen | 14 | $182 | $13 |
| Alendronate | 11 | $135 | $12 |
| Zolpidem | 21 | $111 | $5 |
| Atenolol | 13 | $89 | $7 |
| Allopurinol | 16 | $77 | $5 |
| Fluoxetine | 13 | $73 | $6 |
| Trazodone | 16 | $61 | $4 |
| Amitriptyline | 12 | $54 | $5 |
| Furosemide | 11 | $49 | $4 |
Money from drug and device companies
$19 in 2024
A payment is not proof that care is biased.
| Genentech | None | $19 | 1 payment
|
See the published payment
| Genentech | Meals · 2024-09-23 | None | $19 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| SANOFI US SERVICES INC. · 2021 | Their institution | $145,353 |
Professional record
- NPI
- 1881759421
- Licence
- CA G51537California G51537: Current · expires 2027-10-31
- Trained
- Warren Alpert Medical School of Brown University, 1982
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-12-26
- NPI last updated
- 2024-04-18
- NPI record certified
- 2024-04-18
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1464 Gilmore St, Mountain View, CA, 94040 · Internal Medicine, Stanford, CA, 94305